The US FDA Center for Drug Evaluation and Research’s novel approvals class of 2022 is notable for the absence of very fast reviews – approvals that come within six months of submission, or at least two months in advance of a priority review goal date – marking another way in which the year 2022 reversed course from the agency’s recent past.
Approvals well in advance of the user fee goal date had become almost commonplace during the novel approvals boom. Between 2015 and 2021, very fast reviews accounted for an average of 14% of new molecular entity and novel biologic approvals, peaking in 2019 when 11 novel agents were approved in six months or less, accounting for 23% of CDER approvals
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?